ArticleWorld journal of urology2015
An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high?
Article in World journal of urology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer.The Cochrane database of systematic reviews · 2019Pooled it
- Trial
- Twenty years of age-standardized prostate cancer mortality in Kazakhstan (2005-2024): joinpoint model and geographical hot spot and cold spot analysis.BMC public health · 2026Observational
- Reduced prostate cancer screening has a negative impact on stage migration: the Australian experience.BJU international · 2025Article
- Bayesian Spatio-Temporal Multilevel Modelling of Patient-Reported Quality of Life following Prostate Cancer Surgery.Healthcare (Basel, Switzerland) · 2024Article
- Treatment of rectal cancer after previous prostate cancer: A single institution experience.Oncology letters · 2023Article
- Crude probability of death for cancer patients by spread of disease in New South Wales, Australia 1985 to 2014.Cancer medicine · 2021Article
- Incidence and Mortality of Prostate Cancer in Canada during 1992-2010.Current oncology (Toronto, Ont.) · 2021Article
- Changes in the uptake of screening for prostate cancer with prostate-specific antigen in Ontario between 2003 to 2012.Canadian oncology nursing journal = Revue canadienne de nursing oncologique · 2020Article
- Changements dans les pratiques de dépistage de l'antigène prostatique spécifique en Ontario entre 2003 et 2012.Canadian oncology nursing journal = Revue canadienne de nursing oncologique · 2020Article
- Cytokines expression levels from tissue, plasma or serum as promising clinical biomarkers in adenocarcinoma of the prostate: a systematic review of recent findings.Annals of translational medicine · 2019Review
- Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada.BMC urology · 2019Review
- Article
- The Effect of Targeted Therapy for Genitourinary Malignancies on Sexual Function and Fertility.Current urology reports · 2017Review
- Incidence and mortality of prostate cancer and their relationship with the Human Development Index worldwide.Prostate international · 2016Article
- Article
- Quantifying disparities in cancer incidence and mortality of Australian residents of New South Wales (NSW) by place of birth: an ecological study.BMC public health · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare prostate cancer incidence and mortality rates in Australia, USA, Canada and England and quantify the gap between observed prostate cancer deaths in Australia and expected deaths, using US mortality rates.
methodsAnalysis of age-standardised prostate cancer incidence and mortality rates, using routinely available data, in four similarly developed countries and joinpoint regression to quantify the changing rates (annual percentage change: APC) and test statistical significance. Expected prostate cancer deaths, using US mortality rates, were calculated and compared with observed deaths in Australia (1994-2010).
resultsIn all four countries, incidence rates initially peaked between 1992 and 1994, but a second, higher peak occurred in Australia in 2009 (188.9/100,000), rising at a rate of 5.8 % (1998-2008). Mortality rates in the USA (APC: -2.9 %; 2004-2010), Canada (APC: -2.9 %; 2006-2011) and England (APC: -2.6 %; 2003-2008) decreased at a faster rate compared with Australia (APC: -1.7 %; 1997-2011). In 2010, mortality rates were highest in England and Australia (23.8/100,000 in both countries). The mortality gap between Australia and USA grew from 1994 to 2010, with a total of 10,895 excess prostate cancer deaths in Australia compared with US rates over 17 preceding years.
conclusionsProstate cancer incidence rates are likely heavily influenced by prostate-specific antigen testing, but the fall in mortality occurred too soon to be solely a result of testing. Greater emphasis should be placed on addressing system-wide differences in the management of prostate cancer to reduce the number of men dying from this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.